Drugs / Plasmodium vivax
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02786589 | Jun 2016 → Jul 2020 | non-small cell lung carcinoma | State Key Laboratory of Respiratory Disease | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05924776 | Jul 2024 → Nov 2026 expected | ovarian carcinoma | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasmodium vivax | “Inoculation 1-5 × 10\^6 Plasmodium vivax once” NCT05924776 ↗1“blood-stage infection of Plasmodium vivax” NCT02786589 ↗ |
| Modality | Other / unclassified | “Plasmodium immunotherapy” NCT05924776 ↗ |
| Route | Other | “Inoculation 1-5 × 10\^6 Plasmodium vivax once” NCT05924776 ↗ |